Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective Ligands

ChemMedChem

Volumn 11, Issue 6, 2016, Pages 556-561

  Sahn, James J ^a   Hodges, Timothy R ^a   Chan, Jessica Z ^a   Martin, Stephen F ^a  

^a University of Texas at Austin   (United States)

Author keywords

1,5 methanobenzazepines; norbenzomorphans; Sig2R PGRMC1; sigma 2 receptors

Indexed keywords

8-(4-(3-ETHOXY-3-OXOPROPYL)PIPERAZIN-1-YL)-1,3,4,5-TETRAHYDRO-1,5-METHANOBENZAZEPINE-2-CARBOXYLATE; BENZAZEPINE DERIVATIVE; BENZOMORPHAN DERIVATIVE; LIGAND; MEMBRANE PROTEIN; PGRMC1 PROTEIN, RAT; PIPERAZINE DERIVATIVE; PROGESTERONE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR; SIGMA-2 RECEPTOR;

ANIMAL; CHEMISTRY; GUINEA PIG; METABOLISM; RADIOASSAY; RAT; STEREOISOMERISM; SYNTHESIS;

ANIMALS; BENZAZEPINES; BENZOMORPHANS; GUINEA PIGS; LIGANDS; MEMBRANE PROTEINS; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, PROGESTERONE; RECEPTORS, SIGMA; STEREOISOMERISM;

EID: 84959449141     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201500551     Document Type: Article

References (46)

1. J. D. Sunderhaus, C. Dockendorff, S. F. Martin, Org. Lett. 2007, 9, 4223-4226;
2. J. D. Sunderhaus, C. Dockendorff, S. F. Martin, Tetrahedron 2009, 65, 6454-6469;
3. J. R. Donald, S. F. Martin, Org. Lett. 2011, 13, 852-855;
4. J. R. Donald, R. R. Wood, S. F. Martin, ACS Comb. Sci. 2012, 14, 135-143;
5. S. Hardy, S. F. Martin, Org. Lett. 2011, 13, 3102-3105;
6. B. A. Granger, K. Kaneda, S. F. Martin, Org. Lett. 2011, 13, 4542-4545;
7. B. A. Granger, Z. Wang, K. Kaneda, Z. Fang, S. F. Martin, ACS Comb. Sci. 2013, 15, 379-386;
8. B. A. Granger, K. Kaneda, S. F. Martin, ACS Comb. Sci. 2012, 14, 75-79;
9. J. J. Sahn, B. A. Granger, S. F. Martin, Org. Biomol. Chem. 2014, 12, 7659-7672.
10. J. J. Sahn, J. Su, S. F. Martin, Org. Lett. 2011, 13, 2590-2593.
11. J. J. Sahn, S. F. Martin, ACS Comb. Sci. 2012, 14, 496-502.
12. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 2001, 46, 3-26.
13. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, K. D. Kopple, J. Med. Chem. 2002, 45, 2615-2623.
14. A. E. Jacobson, M. Mokotoff, J. Med. Chem. 1970, 13, 7-9.
15. Y. L. Chen, D. Liston, J. Nielsen, D. Chapin, A. Dunaiskis, K. Hedberg, J. Ives, J. Johnson, Jr., S. Jones, J. Med. Chem. 1994, 37, 1996-2000.
16. J. Xu, M. Chatterjee, T. D. Baguley, J. Brouillette, P. Kurup, D. Ghosh, J. Kanyo, Y. Zhang, K. Seyb, C. Ononenyi, E. Foscue, G. M. Anderson, J. Gresack, G. D. Cuny, M. A. Glicksman, P. Greengard, T. T. Lam, L. Tautz, A. C. Nairn, J. A. Ellman, P. J. Lombroso, PLoS Biol. 2014, 12, e 1001923.
17. See: https://pubchem.ncbi.nlm.nih.gov/assay/bioactivity.html?cid=44825921.
18. C. A. Furman, R. A. Roof, A. E. Moritz, B. N. Miller, T. B. Doyle, R. B. Free, A. K. Banala, N. M. Paul, V. Kumar, C. D. Sibley, A. H. Newman, D. R. Sibley, Eur. Neuropsychopharmacol. 2015, 25, 1448-1461.
19. Binding affinities were determined through a competition binding assay in the presence of a radioligand; for a summary, see the Supporting Information. Detailed protocols can be found within the US National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) Assay Protocol Book (version II), by B. L. Roth, March 2013.
20. S. F. Martin, J. J. Sahn, L. Scott, J. T. Pierce-Shimomura, (Board of Regents, University of Texas System, Austin, Texas, USA), PCT Int. Pat. Appl. WO 2015/009742 A2, 2015.
21. Sigma receptors: Chemistry, cell biology, and clinical implications (Eds.:, R. R. Matsumoto, W. D. Bowen, T. P. Su,), Springer, New York, 2007.
22. J. Xu, C. Zeng, W. Chu, F. Pan, J. M. Rothfuss, F. Zhang, Z. Tu, D. Zhou, D. Zeng, S. Vangveravong, F. Johnston, D. Spitzer, K. C. Chang, R. S. Hotchkiss, W. G. Hawkins, K. T. Wheeler, R. H. Mach, Nat. Commun. 2011, 2, 380.
23. M. A. Cahill, J. Steroid Biochem. Mol. Biol. 2007, 105, 16-36.
24. C. Abate, M. Niso, V. Infantino, A. Menga, F. Berardi, Eur. J. Pharmacol. 2015, 758, 16-23.
25. U. B. Chu, S. Ramachandran, A. R. Hajipour, A. E. Ruoho, Biochemistry 2013, 52, 859-868.
26. L. Guo, X. Zhen, Curr. Med. Chem. 2015, 22, 989-1003.
27. R. H. Mach, C. Zeng, W. G. Hawkins, J. Med. Chem. 2013, 56, 7137-7160.
28. Poster presentation: J. Z. Chan, J. Pierce-Shimomura, S. F. Martin, L. L. Scott, J. J. Sahn, "Investigating Sigma 2 Receptor Ligands for the Targeted Therapeutics of Alzheimer′s Disease by Utilizing a Novel C. elegans Model of AD" (MEDI-97), 247th ACS National Meeting and Exposition, March 16-20, 2014 (Dallas, Texas, USA).
29. J. J. Sahn, L. L. Scott, G. Zuniga, T. Satarasinghe, T. A. Wong, P. M. Ardestani, J. Pierce-Shimomura, M. Shamloo, S. F. Martin, "Development of Novel Therapeutics Targeting Sig2R/PGRMC1 for Alzheimer′s Disease" (abstract 555.05) presented during the session entitled "Sigma Receptors: Emerging Roles in Health and Disease" at the Society for Neuroscience annual conference "Neuroscience 2015", Chicago, IL (USA), October 17-21, 2015. See: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=ce4d5ce6-c0ab-4286-b297-cd646c277edc&cKey=1f3b7a7b-8fd9-4277-ad90-5673549d3fd4&mKey=d0ff4555-8574-4fbb-b9d4-04eec8ba0c84.
30. The pharmacokinetic study of 32 was performed at the Stanford Behavioral and Functional Neuroscience Laboratory (sbfnl.stanford.edu), Director: Mehrdad Shamloo, Ph.D.
31. N. J. Izzo, A. Staniszewski, L. To, M. Fa, A. F. Teich, F. Saeed, H. Wostein, T. Walko III, A. Vaswani, M. Wardius, Z. Syed, J. Ravenscroft, K. Mozzoni, C. Silky, C. Rehak, R. Yurko, P. Finn, G. Look, G. Rishton, H. Safferstein, M. Miller, C. Johanson, E. Stopa, M. Windisch, B. Hutter-Paier, M. Shamloo, O. Arancio, H. LeVine III, S. M. Catalano, PloS one 2014, 9, e 111898.
32. N. J. Izzo, J. Xu, C. Zeng, M. J. Kirk, K. Mozzoni, C. Silky, C. Rehak, R. Yurko, G. Look, G. Rishton, H. Safferstein, C. Cruchaga, A. Goate, M. A. Cahill, O. Arancio, R. H. Mach, R. Craven, E. Head, H. LeVine III, T. L. Spires-Jones, S. M. Catalano, PloS one 2014, 9, e 111899.
33. E. Laurini, D. Zampieri, M. G. Mamolo, L. Vio, C. Zanette, C. Florio, P. Posocco, M. Fermeglia, S. Pricl, Bioorg. Med. Chem. Lett. 2010, 20, 2954-2957.
34. D. J. Rhoades, D. H. Kinder, T. M. Mahfouz, Med. Chem. 2014, 10, 98-121.
35. For a detailed accounting of selective Sig2R/PGRMC1 ligands, see:
36. Y. S. Huang, H. L. Lu, L. J. Zhang, Z. Wu, Med. Res. Rev. 2014, 34, 532-566;
37. S. Narayanan, R. Bhat, C. Mesangeau, J. H. Poupaert, C. R. McCurdy, Future Med. Chem. 2011, 3, 79-94.
38. a values were calculated using ACD/I-Lab software (www.acdlabs.com/resources/ilab/), Advanced Chemistry Development, Inc. (Toronto, Canada).
39. E. H. Kerns, L. Di, Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization, Academic Press, Boston, 2008.
40. T. T. Wager, R. Y. Chandrasekaran, X. Hou, M. D. Troutman, P. R. Verhoest, A. Villalobos, Y. Will, ACS Chem. Neurosci. 2010, 1, 420-434.
41. H. J. Möller, H. P. Volz, I. W. Reimann, K. D. Stoll, J. Clin. Psychophramacol. 2001, 21, 59-65.
42. H. P. Volz, K. D. Stoll, Pharmacopsychiatry 2004, 37, 214-220;
43. D. L. Gilmore, Y. Liu, R. R. Matsumoto, CNS Drug Rev. 2004, 10, 1-22;
44. R. H. Luthringer, L. Pellegrini, A. N. Karabelas, (Cyrenaic Pharmaceuticals Inc., Princeton, USA), PCT Int. Pat. Appl. WO 2012/012543 A1, 2012.
45. Minerva Neurosciences, Inc. Press Release ID 947593: "Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101" (December 18, 2015).
46. "US biotech Cognition Therapeutics tests Alzheimer's drug in Australia", S. J. Tasker, The Australian, September 18, 2015.